Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors

by Balko, Justin M, Potti, Anil, Saunders, Christopher, Stromberg, Arnold, Haura, Eric B, Black, Esther P
Published 2006

Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma

by Schneeberger, Valentina E., Ren, Yuan, Luetteke, Noreen, Huang, Qingling, Chen, Liwei, Lawrence, Harshani R., Lawrence, Nicholas J., Haura, Eric B., Koomen, John M., Coppola, Domenico, Wu, Jie
Published 2015

A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma

by Stewart, Paul A., Parapatics, Katja, Welsh, Eric A., Müller, André C., Cao, Haoyun, Fang, Bin, Koomen, John M., Eschrich, Steven A., Bennett, Keiryn L., Haura, Eric B.
Published 2015

Transforming Growth Factor β Signaling Overcomes Dasatinib Resistance in Lung Cancer

by Gordian, Edna, Li, Jiannong, Pevzner, Yuri, Mediavilla-Varela, Melanie, Luddy, Kimberly, Ohaegbulam, Kim, Daniel, Kenyon G., Haura, Eric B., Muñoz-Antonia, Teresita
Published 2014

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

by Simon, George R., Ilaria, Robert L., Sovak, Mika A., Williams, Charles C., Haura, Eric B., Cleverly, Ann L., Sykes, Amanda K., Wagner, Margaret M., de Alwis, Dinesh P., Slapak, Christopher A., Miller, Mary A., Spriggs, David R.
Published 2011

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

by Yoshida, Takeshi, Song, Lanxi, Bai, Yun, Kinose, Fumi, Li, Jiannong, Ohaegbulam, Kim C., Muñoz-Antonia, Teresita, Qu, Xiaotao, Eschrich, Steven, Uramoto, Hidetaka, Tanaka, Fumihiro, Nasarre, Patrick, Gemmill, Robert M., Roche, Joëlle, Drabkin, Harry A., Haura, Eric B.
Published 2016

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

by Baldelli, Elisa, Bellezza, Guido, Haura, Eric B., Crinó, Lucio, Cress, W. Douglas, Deng, Jianghong, Ludovini, Vienna, Sidoni, Angelo, Schabath, Matthew B., Puma, Francesco, Vannucci, Jacopo, Siggillino, Annamaria, Liotta, Lance A., Petricoin, Emanuel F., Pierobon, Mariaelena
Published 2015

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

by Li, Jiannong, Bennett, Keiryn, Stukalov, Alexey, Fang, Bin, Zhang, Guolin, Yoshida, Takeshi, Okamoto, Isamu, Kim, Jae-Young, Song, Lanxi, Bai, Yun, Qian, Xiaoning, Rawal, Bhupendra, Schell, Michael, Grebien, Florian, Winter, Georg, Rix, Uwe, Eschrich, Steven, Colinge, Jacques, Koomen, John, Superti-Furga, Giulio, Haura, Eric B
Published 2013

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

by Schabath, Matthew B., Welsh, Eric A., Fulp, William J., Chen, Lu, Teer, Jamie K., Thompson, Zachary J., Engel, Brienne E., Xie, Mengyu, Berglund, Anders E., Creelan, Ben C., Antonia, Scott J., Gray, Jhanelle E., Eschrich, Steven, Chen, Dung-Tsa, Cress, W. Douglas, Haura, Eric B., Beg, Amer A.
Published 2015

MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated

by Smida, Michal, Fece de la Cruz, Ferran, Kerzendorfer, Claudia, Uras, Iris Z., Mair, Barbara, Mazouzi, Abdelghani, Suchankova, Tereza, Konopka, Tomasz, Katz, Amanda M., Paz, Keren, Nagy-Bojarszky, Katalin, Muellner, Markus K., Bago-Horvath, Zsuzsanna, Haura, Eric B., Loizou, Joanna I., Nijman, Sebastian M. B.
Published 2016